gefitinib has been researched along with Soft Tissue Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kataoka, K; Okamura, Y; Osaka, E; Shimizu, T; Tokuhashi, Y; Yoshida, Y | 1 |
| Albanell, J; Baselga, J; Gascón, P; González, S; Guillém, V; Koehler, MT; Lluch, A; Marimón, I; Rojo, F; Ruiz, A; Sauleda, S; Tabernero, JM | 1 |
1 trial(s) available for gefitinib and Soft Tissue Neoplasms
| Article | Year |
|---|---|
Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Bone Neoplasms; Breast Neoplasms; Cell Cycle Proteins; Cyclin-Dependent Kinase Inhibitor p27; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Ki-67 Antigen; Male; Maximum Tolerated Dose; Middle Aged; Mitogen-Activated Protein Kinases; Phosphorylation; Quinazolines; Salvage Therapy; Soft Tissue Neoplasms; Treatment Outcome; Tumor Suppressor Proteins | 2005 |
1 other study(ies) available for gefitinib and Soft Tissue Neoplasms
| Article | Year |
|---|---|
Lung squamous cell carcinoma with brachial soft tissue metastasis responsive to gefitinib: Report of a rare case.
Topics: Arm; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Quinazolines; Soft Tissue Neoplasms; Treatment Outcome | 2016 |